Osteoporosis is the most important side effect of long-term steroid treatment.1 Fractures are a frequent consequence of osteoporosis and mainly affect the spine (height loss, kyphosis, severe acute or chronic back pain, and complete immobility).2 In children the management of this complication is difficult particularly when a full dose of steroids is required to control the underlying disease. Recently it has been suggested that Deflazacort (DFL), an oxazolinic acid derivative of prednisone, may have a bone sparing effect when compared with prednisone.
DEFLAZACORT IN PEDIATRIC RHEUMATIC DISEASES NEEDS A FREQUENT FOLLOW-UP OF BONE DENSITOMETRY / F. FALCINI; S. TRAPANI; M. ERMINI; G. BARTOLOZZI. - In: PEDIATRICS. - ISSN 0031-4005. - ELETTRONICO. - 95:(1995), pp. 318-319.
DEFLAZACORT IN PEDIATRIC RHEUMATIC DISEASES NEEDS A FREQUENT FOLLOW-UP OF BONE DENSITOMETRY
FALCINI, FERNANDA
;TRAPANI, SANDRA;M. ERMINI;BARTOLOZZI, GIORGIO
1995
Abstract
Osteoporosis is the most important side effect of long-term steroid treatment.1 Fractures are a frequent consequence of osteoporosis and mainly affect the spine (height loss, kyphosis, severe acute or chronic back pain, and complete immobility).2 In children the management of this complication is difficult particularly when a full dose of steroids is required to control the underlying disease. Recently it has been suggested that Deflazacort (DFL), an oxazolinic acid derivative of prednisone, may have a bone sparing effect when compared with prednisone.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
